This cutting-edge GLP-1 mimicking drug increases insulin production, impacts blood sugar, and supports a healthy metabolismall while significantly reducing your hunger and cravings
Source: Polaris Market Research Analysis Key Players and Competitive Insights Novo Nordisk maintains a dominant position in the semaglutide market through its exclusive rights to develop, manufacture, and commercialize Ozempic, Wegovy, and Rybelsus
Semaglutide is approved for chronic weight management, and long-term use may be appropriate for some individuals
The Cleveland Clinic notes that as many as two thirds of people with diabetes who require injections are affected by lipohypertrophy at some point
At GoodLife Meds, we believe in flexibility and transparency
But if you're on a GLP-1 medication Ozempic, Wegovy, Mounjaro, Trulicity, or any of the others becoming increasingly common across the UK you'll already know that your treatment comes with a few extra things to think about
